Link:  https://journal-neo.org/2021/08/30/scandal-behind-the-fda-fake-approval-of-pfizer-jab/

EXTRACT

Faked Approval

It seems the FDA executed a clever ruse in which it issued separate rulings for a Pfizer Inc.-BioNTech vaccine which is widely used in the USA, and another ruling for the similar vaccine of Pfizer’s German-based partner and developer of the mRNA platform, BioNTech of Mainz. It is only BioNTech that got FDA approval, but conditioned on completion of a series of further tests on select groups including infants, pregnant women and youth, by 2027. The US vaccine, Pfizer-BioNTech Covid-19 vaccine, only got extension of its Emergency Use Authorization (EUA), not full approval!

In their separate letter to Pfizer, the FDA stated, “…On August 23, 2021, having concluded that revising this EUA is appropriate to protect the public health or safety under section 564(g)(2) of the Act, FDA is reissuing the August 12, 2021 letter of (Emergency Use) authorization in its entirety with revisions incorporated to clarify that the EUA will remain in place for the Pfizer-BioNTech COVID-19 vaccine for the previously-authorized indication and uses…”(emphasis added).

Buried in a footnote in the letter the FDA admits there are two legally separate entities and vaccines—Pfizer-BioNTech Covid-19 Vaccine and BioNTech GmbH of Mainz with its own vaccine trade-named Comrinaty. The FDA writes that “The products are legally distinct with certain differences…” Legally distinct means two separate vaccines. If you find this confusing it is meant to be. Only under an EUA ruling is Pfizer presently exempt from vaccine liability. Some lawyers are calling the FDA ruse a classic “bait and switch” tactic, a form of fraud based on deception.

US vaccinologist and a developer of the mRNA technique, Dr Robert Malone, has accused the FDA of playing a “bureaucratic shell game” with their supposed early approval of the Pfizer Covid-19 vaccine. He cites the two separate FDA letters, “There is a letter for Pfizer and a letter for BioNTech. The New York Times and the Washington Post got it wrong. The authorization is not for Pfizer. The authorization is for BioNTech, and it will only be initiated at the time BioNTech product becomes available…”